Skip to search formSkip to main contentSkip to account menu

crizotinib 250 MG Oral Capsule [Xalkori]

Known as: Xalkori 250 MG Oral Capsule 
National Institutes of Health

Related topics

Related topics

16 relations
AmmoniaGelatinMagnesium stearateOral Capsule

Broader (1)

crizotinib 250 MG Oral Capsule

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
XALKORI ® ( Crizotinib ) Receives Approval In European Union For The Treatment Of Patients With ROS 1-Positive Advanced Non-Small Cell Lung Cancer Release
  • 2018
  • Corpus ID: 52236623
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the European Commission has approved XALKORI® (crizotinib… 
2016
2016
Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial".
Anaplastic lymphoma kinase ( ALK )-rearrangements occur in 3–7% of patients with non-small cell lung cancer (NSCLC) and are more… 
2015
2015
Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects
Crizotinib (Xalkori®) is an orally administered, selective, small‐molecule, ATP‐competitive inhibitor of the anaplastic lymphoma… 
Review
2015
Review
2015
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
Crizotinib (XALKORI™, Pfizer) is a tyrosine kinase inhibitor targeting ALK, MET and ROS1, currently approved for the treatment of… 
Review
2015
Review
2015
Review of the use of ceritinib, a newly approved anaplastic lymphoma kinase (ALK) inhibitor, in crizotinib-resistant anaplastic lymphoma kinase-rearranged non-small cell lung cancer
The purpose of this poster is to provide a summary of data on ceritinib, that shows exceptional potency against ALK mutations… 
2014
2014
Liposomes ameliorate Crizotinib- and Nilotinib-induced inhibition of the cardiac IKr channel and QTc prolongation.
Crizotinib (Xalkori®) and nilotinib (Tasigna®) are tyrosine kinase inhibitors approved for the treatment of non-small cell lung… 
2014
2014
Actualités pharmacologiques – le crizotinib (Xalkori®)
Review
2013
Review
2013
Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
Crizotinib (Xalkori®) is an orally active, small molecule inhibitor of multiple receptor tyrosine kinases, including anaplastic… 
2013
2013
Abstract 4464: Elucidation of crizotinib resistance in NCI-H3122 and strategies to circumvent bypass resistance.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC The Anaplastic Lymphoma Kinase (ALK) fusion proteins… 
2013
2013
Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)
An activating mutation of the anaplastic lymphoma kinase (ALK) fusion gene is responsible for 1-7% of non-small lung cancer… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)